美國商業資訊

2025-03-31 19:44

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership.
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease
Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.

Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market1 and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”

NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.

The Company expects this transaction to be neutral to Adjusted EPS2 in year one and accretive thereafter.

GE HealthCare was advised by Solomon Partners Securities, LLC.

The intent to acquire the remaining 50% stake in NMP was announced in December 2024.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedInXFacebookInstagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.

 

Contacts

Media contact
David Morris
Executive, Communications, Pharmaceutical Diagnostics
GE HealthCare
+44 7920591370
david.j.morris@gehealthcare.com

Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.

【你點睇?】中美元首通電話,雙方同意繼續落實日內瓦共識,你認為中美能否於90天關稅停火期內達終極協議?► 立即了解

人氣文章
最近7天
1
高息定存 | 一周高息合集,滙豐兌換外幣資金可享7日10厘,建行亞洲3個月最高5.58厘
2
港股 | 蕭猷華:恒指本周料先低後高
3
無人機 | FOCUS | 無人機出奇制勝,新博弈中國藏王牌
4
美股收盤 | 非農就業數據勝預期,標指重上6000點關口
5
長和:英國《金融時報》報道不盡不實,不反映集團港口交易取態
6
車企血戰 | FOCUS | 車企「口水仗」橫飛,行業陷集體焦慮
7
OCBC宏富理財發佈品牌大使鍾嘉欣 端午聯乘「鴨靈號」閃耀維港 慶祝「新加坡—香港雙樞紐」策略的成功
8
高息定存 | PAObank推港元定存優惠,一個月定存16厘息
9
關稅戰 | 白宮稱特朗普於周二簽署行政命令,上調鋼鋁稅至50%
10
國務院任命周霽為中聯辦主任,接替鄭雁雄
1
開市Go | 美匯下跌後回升,恒瑞招股,騰訊季盈利勝預期
2
電動車 | 哪吒汽車被申請破產,母公司被執行金額逾1億元
3
第八屆兒童書展|5.23開鑼 親子減壓!開心激玩閱讀嘉年華
4
關稅戰 | FOCUS | 中國對美出口挫21%,未來數月臨韌性真考驗
5
市場波動下的攻守之道 2025第二季股巿與輪證部署策略
6
長和:港口交易絕不可能不合法或不合規情況下進行
7
高息定存 | 中銀恒生齊減定存息,3個月及6個月存期失守3厘
8
高息定存 | 滙豐恒生減定存息,3個月最高2.4厘,7日10厘
9
美股收盤 | 三大指數個別發展,市場觀望中美經貿會談
10
高息定存 | 一周高息合集,滙豐單周三度減定存息,建行亞洲3個月仍有4.8厘
11
星展基金會:以創新推動大灣區樂齡經濟
12
寧德時代 | FOCUS | 此「寧王」非彼「雪王」,換電賽道臨雙考驗
13
寧德時代 | David Webb警告寧德時代H股流通股數量過低
14
下調評級 | 債務攀升財赤擴大,穆迪降美國信用評級至AA1
15
港股 | 蕭猷華:恒指5月上望24000點
16
券商轉型生死局:為何科技夥伴成機構「救命稻草」?
17
高息定存 | 一周高息合集,拆息大跌多間港銀下調定存息,工銀亞洲3個月仍有3.05厘
18
高息定存 | 多間銀行下調港元定存年息,滙豐3個月2.8厘
19
高息定存 | 招商永隆上調一年期港元定存息,滙豐3個月跌穿1厘
20
關稅戰 | 特朗普建議6月1日起對歐盟商品徵50%關稅,斥歐盟貿易壁壘嚴重
21
高息定存 | 一周高息合集,三大發鈔行再減存息,工銀亞洲3個月最高5厘
22
關稅戰 | 特朗普轉軚,歐盟50%關稅期限暫緩至7月9日
23
阿里 | 傳與蘋果AI合作受美關注疊加季績遜預期,阿里連日急挫,仍獲大行力撐可趁機吸?
24
美股收盤 | 關稅戰再添變數,三大指數各有升跌
25
高息定存 | 一周高息合集,滙豐兌換外幣資金可享7日10厘,建行亞洲3個月最高5.58厘
26
關稅戰 | 美擬就中國電池材料徵反補貼稅,專家:出於政治考量
27
小米 | 季績勝預期獲大行升目標,股價逆市上升應如何部署?
28
神州經脈 | 比亞迪反擊「汽車圈恒大」質疑,日本水產將恢復進口
29
關稅戰 | 中美關稅戰暫停90日,加稅反制暫緩時間線全梳理
30
關稅戰 | FOCUS | 「共識」VS「協議」藏玄機,稅率回撤細節引關注
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮獲HKEX Awards 2024 「最佳證券數據供應商」大獎

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

貨幣攻略

關稅戰

大國博弈

說說心理話

Watch Trends 2025

北上食買玩

Wonder in Art

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老